Asset Details
Do you wish to reserve the book?
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
Do you wish to request the book?
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
2012
Overview
Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a pooled analysis of 96 recurrent grade III malignant glioma patients enrolled on three consecutive phase II bevacizumab salvage trials to evaluate overall outcome following bevacizumab trial discontinuation. Outcome on the three bevacizumab trials, which included similar eligibility, treatment and assessment criteria, was comparable. Forty-nine patients who progressed on bevacizumab trial therapy and remained alive for at least 30 days elected to receive additional therapy. These patients achieved a median PFS-6 and OS of 30.6% (95% CI: 18.4, 43.6) and 10.3 months (95% CI: 5.2, 11.7), respectively. Among patients who continued bevacizumab therapy (
n
= 23) after study progression, PFS-6 and median OS were 39.1% (95% CI: 19.9, 58.0) and 9.2 months (95% CI: 5.2, 13.6), respectively, compared to 23.1% (95% CI: 9.4, 40.3;
P
= 0.51) and 10.3 months (95% CI: 2.5, 14.4;
P
= 0.91) for patients who initiated non-bevacizumab containing therapy (
n
= 26). Outcome after discontinuation of bevacizumab therapy for recurrent grade III malignant glioma patients is associated with improved outcome compared to historical data for recurrent grade IV malignant glioma patients. Salvage therapies following bevacizumab failure have modest activity for grade III malignant glioma patients that is independent of further bevacizumab continuation.
Publisher
Springer US,Springer Nature B.V
Subject
/ Aged
/ Angiogenesis Inhibitors - therapeutic use
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Brain Neoplasms - drug therapy
/ Clinical Study - Patient Study
/ Female
/ Glioma
/ Humans
/ Male
/ Medicine
/ Neoplasm Recurrence, Local - drug therapy
/ Neoplasm Recurrence, Local - mortality
/ Neoplasm Recurrence, Local - pathology
/ Oncology
